RETA - レアタ・ファ―マシュ―ティカルズ （Reata Pharmaceuticals Inc.）

Reata Pharmaceuticals (RETA) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open.The consensus EPS Estimate is -$1.97 (-49.2% Y/Y) and the…

Reata Pharmaceuticals (NASDAQ: RETA ) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here''s what investors need to know before the announcement. Analysts estimate that Reata Pharmaceuticals will report an earnings per share (EPS) of $-2.02. Reata Pharmaceuticals bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the second quarter ended June 30, 2022, and provide an update on the Company’s business operations and clinical development programs on August 8, 2022, before the U.S. financial markets

Reata Pharmaceuticals Inc. (NASDAQ:RETA) price on Friday, July 29, rose 2.10% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $30.68. A look at the stock’s price movement, the close in the last trading session was $30.05, moving within a range at $29.72 and $30.98. The beta value … Reata Pharmaceuticals Inc.: When The Timing Is Right, Sit Tight Read More »

In the last trading session, 0.87 million shares of the Reata Pharmaceuticals Inc. (NASDAQ:RETA) were traded, and its beta was 1.18. Most recently the company’s share price was $30.95, and it changed around $0.02 or 0.06% from the last close, which brings the market valuation of the company to $1.18B. RETA currently trades at a … Reata Pharmaceuticals Inc. (NASDAQ: RETA) Stock: Can It Surge Further? Read More »

Reata Pharmaceuticals, Inc. (RETA) Soars 5.3%: Is Further Upside Left in the Stock? Nasdaq

The post Movie theater industry has too many screens, former Regal CFO says appeared on BitcoinEthereumNews.com . AMC Entertainments revitalization plan hinges on adding new theaters, but former Regal Entertainment CFO David Ownby told Jefferies there are too many screens in North America. Box office experts agree

AMC Entertainments (NYSE:AMC) revitalization plan hinges on adding new theaters, but former Regal Entertainment CFO David Ownby told Jefferies there are too many screens in North America. Box office experts agree that moviegoing is not going to disappear. The pastime is inexpensive, enjoyable and can drive billions of dollars in ticket sales. In the last two weeks, the domestic box office has set ticket sales records for the pandemic era, a welcome sign of recovery for the industry. Its a particularly promising signal for AMC, which raised around $2 billion in cash over the last six months and plans to use some of the fresh funds to acquire more theater locations. Its best-case scenario is that the public will continue to turn out to see films on the big screen, and with more market share, AMC will reap the benefits of those ticket sales. As AMC moves to add more theaters, its searching for high-performing locations that were abandoned during the pandemic, it may also need to shed some of its underperforming cinemas.

Reata Pharmaceuticals Inc - Class A (RETA) shares closed this week 23.2% higher than it did at the end of last week. The stock is currently up 10.6% year-to-date, down 5.9% over the past 12 months, and up 857.6% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.2%. Trading Activity Shares traded as high as $142.17 and as low as $113.37 this week.Shares closed 3e+1% below its 52-week high and 8e+1% above its 52-week low.Trading volume this week was 5.9% lower than the 10-day average and 14.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -60.8% The company's stock price performance over the past 12 months lags the peer average by -112.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Reata Pharmaceuticals Inc - Class A (RETA) shares closed this week 41.6% higher than it did at the end of last week. The stock is currently down 10.2% year-to-date, down 30.6% over the past 12 months, and up 749.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $114.59 and as low as $77.23 this week.Trading volume this week was 41.8% lower than the 10-day average and 7.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -136.3% The company's stock price performance over the past 12 months lags the peer average by -172.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Reata Pharmaceuticals Inc - Class A (RETA) shares closed this week 41.6% higher than it did at the end of last week. The stock is currently down 10.2% year-to-date, down 30.6% over the past 12 months, and up 749.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $114.59 and as low as $77.23 this week.Trading volume this week was 41.8% lower than the 10-day average and 7.3% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -136.3% The company's stock price performance over the past 12 months lags the peer average by -172.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.